卡瑞利珠单抗联合仑伐替尼一线治疗晚期HCC临床效果及安全性观察OA
Clinical Efficacy and Safety of Camrelizumab Combined with Lenvatinib in First-line Treatment of Advanced HCC
目的:分析卡瑞利珠单抗联合仑伐替尼一线治疗晚期肝细胞癌(hepatocellular carcinoma,HCC)的临床效果及安全性.方法:将九江市第一人民医院 2019 年 1 月—2022 年 1 月HCC患者(80 例)作为研究对象,依据区间随机法将其分为对照组、研究组,各纳入 40 例,对照组行仑伐替尼治疗,研究组行卡瑞利珠单抗联合仑伐替尼一线治疗.比较两组无进展生存期(PFS)、总生存期(OS)、客观缓解率(ORR)与疾病控制率(DCR)、治疗前后肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)]、肿瘤患者功能状态评分(KPS)及治疗期间不良反应发生情况.结果:研究组PFS、OS与对照组相比较长(P<0.05),研究组ORR(75.00%)、DCR(92.50%)均高于对照组的 50.00%、75.00%,差异均有统计学意义(P<0.05);治疗前两组肝功能指标对比差异均无统计学意义(P>0.05),治疗 2 个月后两组ALT、AST、TBIL水平均较治疗前明显降低,研究组均低于对照组(P<0.05);治疗前组间KPS评分对比差异无统计学意义(P>0.05),治疗 2 个月后两组KPS评分均升高,研究组高于对照组(P<0.05);对照组、研究组治疗期间不良反应发生率分别为 12.50%、15.00%,差异无统计学意义(P>0.05).结论:卡瑞利珠单抗联合仑伐替尼一线治疗HCC临床效果理想且安全性具有保障.
Objective:To analyze the clinical efficacy and safety of Camrelizumab combined with Lenvatinib in the first-line treatment of advanced hepatocellular carcinoma(HCC).Method:A total of 80 patients with advanced HCC in Jiujiang NO.1 People's Hospital from January 2019 to January 2022 were taken as the study subjects,and they were divided into control group and study group according to the interval randomization method.The control group was treated with Lenvatinib,and the study group received Camrelizumab combined with Lenvatinib.Progression-free survival(PFS),overall survival(OS),objective response rate(ORR)and disease control rate(DCR),and liver function indicators[aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBIL)]before and after treatment,functional status score(KPS)of tumor patients and the occurrence of adverse reactions during treatment in two groups were compared.Result:The PFS and OS of the study group were longer than those of the control group(P<0.05).The ORR(75.00%)and DCR(92.50%)of the study group were higher than those(50.00%,75.00%)of the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in liver function indexes between the two groups before treatment(P>0.05).After 2 months of treatment,the levels of ALT,AST and TBIL in the two groups were significantly lower than those before treatment,and those in the study group were lower than those in the control group(P<0.05).There was no significant difference in KPS score between the two groups before treatment(P>0.05).After 2 months of treatment,the KPS scores of the two groups increased,and the KPS score of the study group was higher than that of the control group(P<0.05).The incidence of adverse reactions during treatment in the control group and the study group was 12.50%and 15.00%,respectively,the difference was not statistically significant(P>0.05).Conclusion:Camrelizumab combined with Lenvatinib in first-line treatment are effective and safe in HCC.
汤蕾;左宏波;刘秋连;李言冰;夏云;王志;石鑫
九江市第一人民医院肿瘤二科 江西 九江 332000
卡瑞利珠单抗仑伐替尼晚期肝细胞癌安全性
CamrelizumabLenvatinibAdvanced hepatocellular carcinomaSafety
《中国医学创新》 2024 (018)
27-31 / 5
江西省卫生健康委科技计划项目(202211875)
评论